Brazilian Journal of Pain
https://brjp.org.br/article/doi/10.63231/2595-0118.202555-en
Brazilian Journal of Pain
Original Article

Sociodemographic profile, adherence, and drug interactions in patients with chronic pain treated by the Specialized Pharmaceutical Care Component of Blumenau: cross-sectional study

Perfil sociodemográfico, adesão e interações farmacológicas em pacientes com dor crônica atendidos pelo Componente Especializado da Assistência Farmacêutica de Blumenau: estudo transversal

Helena Luiza Kirsten Sasse; Luana Gabriele Nilson; Mônica Cristina Nunes

Downloads: 0
Views: 30

Abstract

JUSTIFICATIVA E OBJETIVOS: Chronic pain (CP) is a multifactorial condition that significantly affects patients’ quality of life. Classified according to its pathophysiological mechanism, CP presents a variety of therapeutic challenges, in addition to its significant economic and social impact. The aim of this study was to define the sociodemographic profile, assess drugs adherence and potential drug interactions of patients diagnosed with chronic pain who take their drugs from the Specialized Component of Pharmaceutical Assistance (CEAF - Componente Especializado da Assistência Farmacêutica).

METHODS: Two instruments were used to assess drug adherence: the Morisky-Green Test (TMG) and the Brief Medication Questionnaire (BMQ). To evaluate the agreement between them, the Kappa coefficient was applied. There was a prevalence of women, white, predominantly aged between 40 and 59, married and with incomplete primary education. The search for drug interactions identified the concomitant use of gabapentin and tramadol, resulting in a high-risk interaction.

RESULTS: The results of the TMG indicated 65% of patients with moderate adherence and the BMQ 60% with probable low adherence, with 95% scoring in the recall domain. The Kappa coefficient showed moderate agreement at 0.58.

CONCLUSION: Pharmaceutical monitoring is essential to guide the use of drugs, identifying interactions and promoting greater adherence to treatment.

Keywords

Chronic pain; Drugs from the Specialized; Drug interactions; Drug therapy; Component of Pharmaceutical Care; Medication adherence

Resumo

JUSTIFICATIVA E OBJETIVOS: A dor crônica (DC) é uma condição multifatorial que afeta significativamente a qualidade de vida dos pacientes. Classificada segundo seu mecanismo fisiopatológico, a DC apresenta desafios terapêuticos variados, além do seu significativo impacto econômico e social. O objetivo deste estudo foi definir o perfil sociodemográfico, avaliar a adesão farmacológica e as interações farmacológicas potenciais de pacientes diagnosticados com DC que retiram seu fármaco no Componente Especializado da Assistência Farmacêutica (CEAF).

MÉTODOS: Foram aplicados dois instrumentos de avaliação da adesão ao tratamento: o teste de Morisky-Green (TMG) e o Brief Medication Questionnaire (BMQ). Para verificar a concordância entre eles, utilizou-se o coeficiente Kappa. Houve prevalência de mulheres, cor branca, faixa etária predominante entre 40 e 59 anos, casados e ensino fundamental incompleto. A busca por interações farmacológicas identificou o uso concomitante de gabapentina e tramadol resultando em interação de risco elevado.

RESULTADOS: Os resultados do TMG indicaram 65% dos pacientes com moderada adesão e o BMQ 60% de provável baixa adesão, sendo que 95% pontuaram no domínio recordação. O coeficiente Kappa apresentou concordância moderada de 0,58.

CONCLUSÃO: O acompanhamento farmacêutico tornasse fundamental para orientar o uso dos fármacos, identificando interações e promovendo maior adesão ao tratamento.

Palavras-chave

Adesão à medicação; Dor crônica; Interações farmacológicas; Medicamentos do Componente Especializado da Assistência Farmacêutica; Tratamento farmacológico

References

1 Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ, Stevens B, Sullivan MD, Tutelman PR, Ushida T, Vader K. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976-82. https://doi.org/10.1097/j.pain.0000000000001939. PMid:32694387.

2 Aguiar DP, Souza CPDQ, Barbosa WJM, Santos FFU Jr, Oliveira ASD. Prevalence of chronic pain in Brazil: systematic review. BrJP. 2021;4(3):257-67. https://doi.org/10.5935/2595-0118.20210041.

3 Chimenti RL, Frey-law LA, Sluka KA. A mechanism-based approach to physical therapist management of pain. Phys Ther. 2018;98(5):302-14. https://doi.org/10.1093/ptj/pzy030. PMid:29669091.

4 Souza JB, Grossmann E, Perissinotti DMN, Oliveira JO Jr, Fonseca PRB, Posso IP. Prevalence of chronic pain, treatments, perception, and interference on life activities: Brazilian population-based survey. Pain Res Manag. 2017;2017:4643830. https://doi.org/10.1155/2017/4643830. PMid:29081680.

5 Rocha ADX, Alfieri FM, Silva NCDOVE. Prevalence of chronic pain and associated factors in a small town in southern Brazil. BrJP. 2021;4(3):225-31. https://doi.org/10.5935/2595-0118.20210040.

6 Mendes EV. As redes de atenção à saúde. Cien Saude Colet. 2010;15(5):2297-305. https://doi.org/10.1590/S1413-81232010000500005. PMid:20802863.

7 Capucho HC, Brito A, Maiolino A, Kaliks RA, Pinto RP. Incorporação de medicamentos no SUS: comparação entre oncologia e componente especializado da assistência farmacêutica. Cien Saude Colet. 2022;27(6):2471-9. https://doi.org/10.1590/1413-81232022276.16282021. PMid:35649033.

8 Brasil. Ministério da Saúde. Portaria Conjunta SAES/SAPS/SECTICS nº 1, de 22 de agosto de 2024. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Dor Crônica. Diário Oficial da União [Internet]; Brasília; 2024 [citado 2025 jun 30]. https://www.gov.br/conitec/pt-br/midias/protocolos/dorcronica-1.pdf

9 Brasil. Ministério da Saúde. Relação Nacional de Medicamentos Essenciais 2022 [Internet]. Brasília: Ministério da Saúde; 2022 [citado 2025 jun 30]. https://bvsms.saude.gov.br/rename-2022/

10 Svarstad BL, Chewning BA, Sleath BL, Claesson C. The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999;37(2):113-24. https://doi.org/10.1016/S0738-3991(98)00107-4. PMid:14528539.

11 Ben AJ, Neumann CR, Mengue SS. Teste de Morisky-Green e Brief Medication Questionnaire para avaliar adesão a medicamentos. Rev Saude Publica. 2012;46(2):279-89. https://doi.org/10.1590/S0034-89102012005000013. PMid:22331180.

12 Lowry R. VassarStats: website for statistical computation [Internet]. 2025 [citado 2025 jun 30]. http://www.vassarstats.net/kappa.html

13 Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74. https://doi.org/10.2307/2529310. PMid:843571.

14 Drugs.com. Drug interaction checker [Internet]. 2025 [citado 2025 jun 30]. https://www.drugs.com/drug_interactions.html

15 Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an internet-based survey. J Pain. 2010;11(11):1230-9. https://doi.org/10.1016/j.jpain.2010.07.002. PMid:20797916.

16 Blyth FM, March LM, Brnabic AJ, Jorm LR, Williamson M, Cousins MJ. Chronic pain in Australia: a prevalence study. Pain. 2001;89(2-3):127-34. https://doi.org/10.1016/S0304-3959(00)00355-9. PMid:11166468.

17 Chinchilla PA, Moyano J. Efficacy of opioids and non-opioid analgesics in the treatment of post procedure pain of burned patients: a narrative review. Braz J Anesthesiol. 2022;72(5):637-47. https://doi.org/10.1016/j.bjane.2021.07.022. PMid:34364900.

18 Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47(3):533-43. PMid:2316538.

19 Xia S-H, Hu SW, Ge DG, Liu D, Wang D, Zhang S, Zhang Q, Yuan L, Li YQ, Yang JX, Wu P, Zhang H, Han MH, Ding HL, Cao JL. Chronic pain impairs memory formation via disruption of neurogenesis mediated by mesohippocampal brain-derived neurotrophic factor signaling. Biol Psychiatry. 2020;88(8):597-610. https://doi.org/10.1016/j.biopsych.2020.02.013. PMid:32307038.

20 Mazza S, Frot M, Rey A. A comprehensive literature review of chronic pain and memory. Prog Neuropsychopharmacol Biol Psychiatry. 2018;87(Pt B):183-92. https://doi.org/10.1016/j.pnpbp.2017.08.006. PMid:28797640.

21 Zhang X, Gao R, Zhang C, Chen H, Wang R, Zhao Q, Zhu T, Chen C. Evidence for cognitive decline in chronic pain: a systematic review and meta-analysis. Front Neurosci. 2021;15:737874. https://doi.org/10.3389/fnins.2021.737874. PMid:34630023.

22 Silva ERCT, Moura MMDA, Siqueira ECD. Transtornos relacionados ao uso de opioides. Revista Eletrônica Acervo Saúde. 2024;24(4):e14637. https://doi.org/10.25248/reas.e14637.2024.

23 Moreno RA, Moreno DH, Soares MB, Ratzke R. Anticonvulsivantes e antipsicóticos no tratamento do transtorno bipolar. Rev Bras Psiquiatr. 2004;26(Suppl 3):37-43. https://doi.org/10.1590/S1516-44462004000700009. PMid:15597138.

24 Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67-74. https://doi.org/10.1097/00005650-198601000-00007. PMid:3945130.

25 Timmerman L, Stronks DL, Groeneweg JG, Huygen FJ. Prevalence and determinants of medication non‐adherence in chronic pain patients: a systematic review. Acta Anaesthesiol Scand. 2016;60(4):416-31. https://doi.org/10.1111/aas.12697. PMid:26860919.

26 Soares CR, Pinto Okuno MF. Fatores associados a adesão e barreiras a terapêutica medicamentosa: relação com o apoio social em idosos. Rev Pesqui Cuid Fundam Online. 2024;16:e13016. https://doi.org/10.9789/2175-5361.rpcfo.v16.13016.

27 Claudino TDS, Lacerda A. Avaliação da adesão ao tratamento imunossupressor em pacientes transplantados renais da cidade de Cruz Alta – RS. Saude Rev Cent Cienc Saude. 2020;46(2). https://doi.org/10.5902/2236583448312.

28 Abdul Ghafur NA, Zaini S, Mizher H. Assessment of methods to measure adherence of antidepressants: a systematic review. JOP. 2024;4(2):260-78. https://doi.org/10.31436/jop.v4i2.287.

29 Pereira PF, Pinheiro AL, Zambra AL, Bortolotto JW, Deuschle VCNK, Bonfanti-Azzolin G. Adesão medicamentosa em idosos polimedicados em uma unidade de atenção básica. Saúde Desenvolv. Hum. 2022;10(1):21. https://doi.org/10.18316/sdh.v10i1.7354.
 


Submitted date:
06/30/2026

Accepted date:
11/14/2025

69721d54a953952d1728eff4 brjp Articles
Links & Downloads

BrJP

Share this page
Page Sections